Plain-English translation of NCT07339059 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach for people with advanced small cell lung cancer that has not progressed after initial chemotherapy and immunotherapy. The study combines a drug called with one of two immunotherapy medications ( or ) to see if this combination can help keep the cancer under control longer than immunotherapy alone.
Small cell lung cancer is aggressive and comes back quickly, even after successful chemotherapy. Current immunotherapy treatments only modestly improve survival, so researchers are looking for ways to enhance treatment results by adding this new medication to help sustain the benefits of initial therapy.
You likely qualify if…
You likely don't qualify if…
You would receive by IV infusion twice per week (on days 1 and 8 of each 3-week cycle), plus one of two immunotherapy drugs by IV infusion once every 3 weeks. You would attend regular clinic visits for treatment, blood tests, and imaging scans to monitor how you are responding. The trial is enrolling 35 people total and is currently recruiting participants.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States